London, UK (PRWEB) July 10, 2014
Notwithstanding its considerable patient pool across the US and 5EU acne market has remained stagnant over the past few decades, with no new drugs coming into the arena. The market has seen a shift toward reformulations of existing products and/or fixed-dose combination (FDC) therapies. Examples of the latter comprise combination products offered by the leading dermatology companies, such as Galderma’s Epiduo, Astellas’ Zineryt, and GlaxoSmithKline’s (GSK) Duac.
Studies have shown that it is possible to enhance compliance, and consequently efficiency, by the synergistic combination of two active ingredients. Meantime, new formulations include liposomes, microsponges, aerosol foams, subantimicrobial-dose doxycycline, nanoemulsions and extended-release minocycline. Reformulations are a low-risk strategy for the big pharma industry players, in comparison with placing funds into new molecular substances for acne. Furthermore, during the oncoming decade, other dermatology players are expected to target the previously untapped paediatric market, as acne has become more prevalent in children younger than 12 years old than it once was, potentially owing to the decreasing age of puberty onset.
Across the six major pharma markets, the pharmacological therapy sales for acne are forecast to reach grow from USD 2.3 billion in 2012 to more than USD 2.8 billion by 2018-end, posting a CAGR of around 4%.
In-demand research report “OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018” prepared by GlobalData is now available at MarketPublishers.com.
Title: OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018
Published: June, 2014
Price: US$ 5,995.00
The report presents a detailed analysis of the acne prescription therapeutics market in the US and 5EU countries – France, Italy, Germany, Spain, and the UK. It presents an brief overview of acne (epidemiology, pathophysiology, etiology, symptoms and existing treatment modes); features annualised market revenue, cost of therapy per year and treatment usage pattern data (2012-2018); provides a strategic assessment of products; characterises the marketplace; identifies key unmet needs, examines research and development strategies, offers clinical trials information, and gives a benchmarking analysis. An exhaustive pipeline analysis is included, too. Furthermore, the report analyses the market competition (as of now and in the future); as well as sheds light on the key restraints, drivers and challenges in the industry.
Reasons to Buy:
More in-demand research reports by the publisher can be found at GlobalData page.